BioCentury | Apr 14, 2017
Company News

ConverGene, NIH deal

...antagonists of dopamine D2 receptors, including lead molecules in ConverGene's preclinical CVG-101 program. According to ConverGene's...
...2016 ). ConverGene LLC , Cambridge, Md. National Institutes of Health , Bethesda, Md. Business: Cancer Julian Zhu ConverGene LLC National...
BioCentury | Dec 16, 2016
Company News

NIH, ConverGene deal

...said. ConverGene and NCATS co-developed the portfolio under a cooperative research and development agreement (CRADA). ConverGene...
...terms. National Institutes of Health , Bethesda, Md. ConverGene LLC , Cambridge, Md. Business: Cancer, Other Alex Himes ConverGene LLC NIH BET...
BioCentury | Dec 15, 2016
Company News

ConverGene advances NCATS collaboration

...to a portfolio of compounds targeting BET bromodomain proteins to treat or prevent mammalian diseases. ConverGene...
...the compounds' core structures in-house, Executive Director of Partnering and Strategy Elizabeth Smith told BioCentury. ConverGene...
...and NCATS co-developed the portfolio under a Cooperative Research and Development Agreement (CRADA). Smith said ConverGene...
Items per page:
1 - 3 of 3
BioCentury | Apr 14, 2017
Company News

ConverGene, NIH deal

...antagonists of dopamine D2 receptors, including lead molecules in ConverGene's preclinical CVG-101 program. According to ConverGene's...
...2016 ). ConverGene LLC , Cambridge, Md. National Institutes of Health , Bethesda, Md. Business: Cancer Julian Zhu ConverGene LLC National...
BioCentury | Dec 16, 2016
Company News

NIH, ConverGene deal

...said. ConverGene and NCATS co-developed the portfolio under a cooperative research and development agreement (CRADA). ConverGene...
...terms. National Institutes of Health , Bethesda, Md. ConverGene LLC , Cambridge, Md. Business: Cancer, Other Alex Himes ConverGene LLC NIH BET...
BioCentury | Dec 15, 2016
Company News

ConverGene advances NCATS collaboration

...to a portfolio of compounds targeting BET bromodomain proteins to treat or prevent mammalian diseases. ConverGene...
...the compounds' core structures in-house, Executive Director of Partnering and Strategy Elizabeth Smith told BioCentury. ConverGene...
...and NCATS co-developed the portfolio under a Cooperative Research and Development Agreement (CRADA). Smith said ConverGene...
Items per page:
1 - 3 of 3